Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration

Journal of Virology

Volumn 78, Issue 16, 2004, Pages 8421-8436

  Logan, Aaron C ^a,b   Haas, Dennis L ^a,b   Kafri, Tal ^c   Kohn, Donald B ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; SIGNAL PEPTIDE;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DNA MODIFICATION; DRUG DESIGN; ENHANCER REGION; GENE ACTIVITY; GENE DELETION; GENE INACTIVATION; GENE MUTATION; GENE SEQUENCE; GENE THERAPY; GENE VECTOR; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION INITIATION; VIRUS CAPSID; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS PARTICLE;

BASE SEQUENCE; CELL LINE; GENETIC VECTORS; GENOME, VIRAL; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS (GENETICS); TRANSCRIPTION, GENETIC; TRANSDUCTION, GENETIC; VIRUS ASSEMBLY; VIRUS INTEGRATION;

EID: 3543147096     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.16.8421-8436.2004     Document Type: Article

References (61)

1. Bukovsky, A. A., J.-P. Song, and L. Naldini. 1999. Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J. Virol. 73:7087-7092.
2. Burns, J. C., T. Friedmann, W. Driever, M. Burrascano, and J.-K. Yee. 1993. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA 90:8033-8037.
3. Case, S. S., M. A. Price, C. T. Jordan, X. J. Yu, L. Wang, G. Bauer, D. L. Haas, D. Xu, R. Stripecke, L. Naldini, D. B. Kohn, and G. M. Crooks. 1999. Stable transduction of quiescent CD34+CD38- human hematopoietic cells by HIV-1-based lentiviral vectors. Proc. Natl. Acad. Sci. USA 96:2988-2993.
4. Chun, T.-W., L. Stuyver, S. B. Mizell, L. A. Ehler, J. A. M. Mican, M. Baseler, A. L. Lloyd, M. A. Nowak, and A. S. Fauci. 1997. Presence of an inducible HIV-1 latent reservoir during highly active retroviral therapy. Proc. Natl. Acad. Sci. USA 94:13193-13197.
5. Clever, J. L., and T. G. Parslow. 1997. Mutant human immunodeficiency virus type 1 genomes with defects in RNA dimerization or encapsidation. J. Virol. 71:3407-3414.
6. Clever, J. L., D. Miranda, and T. G. Parslow. 2002. RNA structure and packaging signals in the 5′ leader region of the human immunodeficiency virus type 1 genome. J. Virol. 76:12381-12387.
7. Curran, M. A., S. M. Kaiser, P. L. Achacoso, and G. P. Nolan. 2000. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol. Ther. 1:31-38.
8. D'Costa, J., H. M. Brown, P. Kundra, A. Davis-Warren, and S. K. Arya. 2001. Human immunodeficiency virus type 2 lentiviral vectors: packaging signal and splice donor in expression and encapsidation. J. Gen. Virol. 82:425-434.
9. Dull, T., R. Zufferey, M. Kelly, R. J. Mandel, M. Nguyen, D. Trono, and L. Naldini. 1998. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72:8463-8471.
10. El Kharroubi, A., and E. Verdin. 1994. Protein-DNA interactions within DNase I-hypersensitive sites located downstream of the HIV-1 promoter. J. Biol. Chem. 269:19916-19924.
11. El Kharroubi, A., and M. A. Martin. 1996. Cis-acting sequences located downstream of the human immunodeficiency virus type 1 promoter affect its chromatin structure and transcriptional activity. Mol. Cell. Biol. 16:2958-2966.
12. Estable, M. C., B. Bell, A. Merzouki, J. S. G. Montaner, M. V. O'Shaughnessy, and I. J. Sadowski. 1996. Human immunodeficiency virus type 1 long terminal repeat variants from 42 patients representing all stages of infection display a wide range of sequence polymorphism and transcriptional activity. J. Virol. 70:4053-4062.
13. Evans, J. T., P. F. Kelly, E. O'Neill, and J. V. Garcia. 1999. Human cord blood CD34+CD38- cell transduction via lentivirus-based gene transfer vectors. Hum. Gene Ther. 10:1479-1489.
14. Evans, J. T., and J. V. Garcia. 2000. Lentivirus vector mobilization and spread by human immunodeficiency virus. Hum. Gene Ther. 11:2331-2339.
15. Farson, D., R. Witt, R. McGuinness, T. Dull, M. Kelly, J. Song, R. Radeke, A. Bukovsky, A. Consiglio, and L. Naldini. 2001. A new-generation stable inducible packaging cell line for lentiviral vectors. Hum. Gene Ther. 12:981-997.
16. Frankel, A. D., and C. O. Pabo. 1988. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55:1189-1193.
17. Garber, M. E., and K. A. Jones. 1999. HIV-1 tat: coping with negative elongation factors. Curr. Opin. Immunol. 11:460-465.
18. Gossen, M., and H. Bujard. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89:5547-5551.
19. Greatorex, J., J. Gallego, G. Varani, and A. Lever. 2002. Structure and stability of wild-type and mutant RNA internal loops from the SL-1 domain of the HIV-1 packaging signal. J. Mol. Biol. 322:543-557.
20. Haas, D. L., S. S. Case, G. M. Crooks, and D. B. Kohn. 2000. Critical factors influencing stable transduction of human CD34+ cells with HIV-1-derived lentiviral vectors. Mol. Ther. 2:71-80.
21. Harrison, G. P., G. Miele, E. Hunter, and A. M. Lever. 1998. Functional analysis of the core human immunodeficiency virus type 1 packaging signal in a permissive cell line. J. Virol. 72:5886-5896.
22. Henderson, A., M. Bunce, N. Siddon, R. Reeves, and D. J. Tremethick. 2000. High-mobility-group protein I can modulate binding of transcription factors to the U5 region of the human immunodeficiency virus type 1 proviral promoter. J. Virol. 74:10523-10534.
23. Iwakuma, T., Y. Cui, and L.-J. Chang. 1999. Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 261:120-132.
24. Jones, K. A., P. A. Luciw, and N. Duchange. 1988. Structural arrangements of transcription control domains within the 5′-untranslated leader regions of the HIV-1 and HIV-2 promoters. Genes Dev. 2:1101-1114.
25. Kafri, T., H. van Praag, L. Ouyang, F. H. Cage, and I. M. Verma. 1999. A packaging cell line for lentivirus vectors. J. Virol. 73:576-584.
26. Konvalinka, J., M. A. Litterst, R. Welker, H. Kottler, F. Rippmann, A.-M. Heuser, and H.-G. Kräusslich. 1995. An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity. J. Virol. 69:7180-7186.
27. Lander, E. S., et al. 2001. Initial sequencing and analysis of the human genome. Nature 409:860-921.
28. Lenz, C., A. Scheid, and H. Schaal. 1997. Exon 1 leader sequences downstream of U5 are important for efficient human immunodeficiency virus type 1 gene expression. J. Virol. 71:2757-2764.
29. Liang, C., X. Li, Y. Quan, M. Laughrea, L. Kleiman, J. Hiscott, and M. A. Wainberg. 1997. Sequence elements downstream of the human immunodeficiency virus type 1 long terminal repeat are required for efficient viral gene transcription. J. Mol. Biol. 272:167-177.
30. Lois, C., E. J. Hong, S. Pease, E. J. Brown, and D. Baltimore. 2002. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295:868-872.
31. Lyons, R. M., S. Forry-Schaudies, E. Otto, C. Wey, V. Patil-Koota, M. Kaloss, G. J. McGarrity, and Y. L. Chiang. 1995. An improved retroviral vector encoding the herpes simplex virus thymidine kinase gene increases antitumor efficacy in vivo. Cancer Gene Ther. 2:273-280.
32. Mallardo, M., E. Dragonetti, F. Baldassarre, C. Ambrosino, G. Scala, and I. Quinto. 1996. An NF-kB site in the 5′-untranslated leader region of the human immunodeficiency virus type 1 enhances the viral expression in response to NF-kB-activating stimuli. J. Biol. Chem. 271:20820-20827.
33. Miyoshi, H., U. Blomer, M. Takahashi, F. H. Gage, and I. M. Verma. 1998. Development of a self-inactivating lentivirus vector. J. Virol. 72:8150-8157.
34. Miyoshi, H., K. A. Smith, D. E. Mosier, I. M. Verma, and B. E. Torbett. 1999. Efficient transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 283:682-686.
35. Naldini, L., U. Blomer, P. Gallay, D. Ory, R. Mulligan, F. H. Gage, I. M. Verma, and D. Trono. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267.
36. O'Rourke, J. P., G. C. Newbound, D. B. Kohn, J. C. Olsen, and B. A. Bunnell. 2002. Comparison of gene transfer efficiencies and gene expression levels achieved with equine infectious anemia virus- and human immunodeficiency virus type 1-derived lentivirus vectors. J. Virol. 76:1510-1515.
37. Pandya, S., K. Boris-Lawrie, N. J. Leung, R. Akkina, and V. Planelles. 2001. Development of a Rev-independent, minimal simian immunodeficiency virus-derived vector system. Hum. Gene Ther. 12:847-857.
38. Poeschla, E. M., F. Wong-Staal, and D. J. Looney. 1998. Efficient transduction of non-dividing human cells by feline immunodeficiency virus lentiviral vectors. Nat. Med. 4:354-357.
39. Quandt, K., K. Frech, H. Karas, E. Wingender, and T. Werner. 1995. MatInd and MatInspector-new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res. 23:4878-4884.
40. Quivy, V., and C. Van Lint. 2002. Diversity of acetylation targets and roles in transcriptional regulation: the human immunodeficiency virus type 1 promoter as a model system. Biochem. Pharmacol. 64:925-934.
41. Rittner, K., M. J. Churcher, M. J. Gait, and J. Karn. 1995. The human immunodeficiency virus long terminal repeat includes a specialized initiator element which is required for tat-responsive transcription. J. Mol. Biol. 248:562-580.
42. Roy, A. L., M. Meisterernst, P. Pognonec, and R. G. Roeder. 1991. Cooperative interaction of an initiator-binding transcription initiation factor and the helix-loop-helix activator USF. Nature 354:245-248.
43. Salmon, P., V. Kindler, O. Ducrey, B. Chapuis, R. H. Zubler, and D. Trono. 2000. High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood 96:3392-3398.
44. Sastry, L., T. Johnson, M. J. Hobson, B. Smucker, and K. Cornetta. 2002. Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther. 9:1155-1162.
45. Schnell, T., P. Foley, M. Wirth, J. Munch, and K. Uberla. 2000. Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum. Gene Ther. 11:439-447.
46. Schroder, A. R. W., P. Shinn, H. Chen, C. Berry, J. R. Ecker, and F. Bushman. 2002. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110:521-529.
47. Smale, S. T. 1997. Transcription initiation from TATA-less promoters within eukaryotic protein-encoding genes. Biochim. Biophys. Acta 1351:73-88.
48. Soneoka, Y., P. M. Cannon, E. E. Ramsdale, J. C. Griffiths, G. Romano, S. M. Kingsman, and A. J. Kingsman. 1995. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 23:628-633.
49. Sonza, S., A. Maerz, N. Deacon, J. Meanger, J. Mills, and S. Crowe. 1996. Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes. J. Virol. 70:3863-3869.
50. Sutton, R. E., M. J. Reitsma, N. Uchida, and P. O. Brown. 1999. Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell-cycle dependent. J. Virol 73:3649-3660.
51. Uchida, N., R. E. Sutton, A. M. Friera, D. He, M. J. Reitsma, W. C. Chang, G. Veres, R. Scollay, and I. L. Weissman. 1998. HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 95:11939-11944.
52. Van Lint, C., C. A. Amella, S. Emiliani, M. John, T. Jie, and E. Verdin. 1997. Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity. J. Virol. 71:6113-6127.
53. Wu, X., J. K. Wakefield, H. Liu, H. Xiao, R. Kralovics, J. T. Prchal, and J. C. Kappes. 2000. Development of a novel trans-lentiviral vector that affords predictable safety. Mol. Ther. 2:47-55.
54. Xu, K., H. Ma, T. J. McCown, I. M. Verma, and T. Kafri. 2001. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol. Ther. 3:97-104.
55. Zeffman, A., S. Hassard, G. Varani, and A. Lever. 2000. The major HIV-1 packaging signal is an extended bulged stem loop whose structure is altered on interaction with the Gag polyprotein. J. Mol. Biol. 297:877-893.
56. Zenzie-Gregory, B., P. Sheridan, K. A. Jones, and S. T. Smale. 1993. HIV-1 core promoter lacks a simple initiator element but contains a bipartite activator at the transcription start site. J. Biol. Chem. 268:15823-15832.
57. Zhang, Y., and E. Barklis. 1995. Nucleocapsid protein effects on the specificity of retrovirus RNA encapsidation. J. Virol. 69:5716-5722.
58. Zhou, Q., D. Chen, E. Pierstorff, and K. Luo. 1998. Transcription elongation factor P-TEFb mediates tat activation of HIV-1 transcription at multiple stages. EMBO J. 17:3681-3691.
59. Zufferey, R., D. Nagy, R. J. Mandel, L. Naldini, and D. Trono. 1997. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15:871-875.
60. Zufferey, R., T. Dull, R. J. Mandel, A. Bukovsky, D. Quiroz, L. Naldini, and D. Trono. 1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72:9873-9880.
61. Zuker, M. 2003. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31:3406-3415.